Physician profile
Federico E Campos
NPI 1497764294
$3,096.82
in general payments reported to CMS, 2019-2025
15 companies · $879 in 2025
The $879 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $621 · 2023: $542 · 2024: $952 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $476.09 | 2024-2025 | Epclusa |
| Amgen INC. | $409.64 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $358.37 | 2023-2025 | Jynarque |
| Madrigal Pharmaceuticals | $287.38 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $235.75 | 2023 | |
| Intercept Pharmaceuticals, INC. | $181.22 | 2023 | Ocaliva |
| Abbott Laboratories | $175.51 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.24 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $142.75 | 2024 | Iqirvo |
| Vertos Medical, INC. | $128.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.83 | 2024 | Jynarque |
| Janssen Pharmaceuticals, INC | $109.29 | 2025 | Spravato |
| Biogen, INC. | $93.19 | 2024 | Spinraza |
| Sanofi-Aventis U.S. LLC | $80.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Federico Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.